Neurocrine Biosciences Inc (NBIX) Stock Price & Analysis
Neurocrine Biosciences Inc (NBIX) fell 1.71% to USD 155.64 as of September 8, 2026 at 05:02 UTC, according to Nexqual real-time market data.
NBIX last closed at USD 155.64; the session ranged USD 154.83–159.8 on volume of 933,569 shares. Market capitalization is —, with a 52-week range of USD 122.14–186.12 (NMS). Source: Nexqual, September 8, 2026 at 05:02 UTC.
Key Statistics (as of September 8, 2026 at 05:02 UTC)
| Price | USD 155.64 |
|---|---|
| Change | ▼ 1.71% (down) |
| Previous Close | USD 155.64 |
| Open | USD 155.64 |
| Day Range | USD 154.83 – 159.8 |
| 52-Week Range | USD 122.14 – 186.12 |
| Volume | 933,569 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (NBIX)
Nexqual's technical model rates NBIX "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 05:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.82 (neutral) |
| vs SMA50 | Below (USD 165.87) |
| MACD | -2.38 (negative) |
From Neurocrine Biosciences Inc's Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- By harnessing both novel validated mechanisms and our proprietary platforms, we aim to launch, on average, approximately one new medicine every two years, driving long-term value for patients and shareholders. 5 The following chart summarizes select clinical development programs.
- Our confidence in this approach is bolstered by our internal know-how of over 30 years studying CRF biology and the success of our first CRF program in CAH. 8 Research and Discovery Engine and Ongoing Innovation Underpinning all our programs is a reinvigorated research and discovery engine that we have built to be both innovative and efficient.
- This focused distribution model allows us to closely manage product supply and support services.
- We believe our outsourced manufacturing strategy enables us to direct our financial resources to maximize our commercial opportunities with INGREZZA and CRENESSITY, invest in our internal research and development programs, and expand our clinical pipeline through business development opportunities.
Partnerships
- Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 266.11 | ▼ 0.48% |
| ALKS | Alkermes plc | USD 46.1 | ▼ 3.39% |
| INCY | Incyte Corporation | USD 126.75 | ▼ 1.61% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 66.53 | ▼ 0.66% |
| UTHR | United Therapeutics Corporation | USD 487.61 | ▼ 0.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:02 UTC. This page is informational and not investment advice.